These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9516863)
1. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children. Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B; Brodeur GM Eur J Cancer; 1997 Oct; 33(12):2106-12. PubMed ID: 9516863 [TBL] [Abstract][Full Text] [Related]
2. A population-based study of the usefulness of screening for neuroblastoma. Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429 [TBL] [Abstract][Full Text] [Related]
3. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project. Takeuchi LA; Hachitanda Y; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD Cancer; 1995 Dec; 76(11):2363-71. PubMed ID: 8635044 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578 [TBL] [Abstract][Full Text] [Related]
5. Screening of infants and mortality due to neuroblastoma. Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470 [TBL] [Abstract][Full Text] [Related]
6. Screening for neuroblastoma in North America. 2-year results from the Quebec Project. Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396 [TBL] [Abstract][Full Text] [Related]
7. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340 [TBL] [Abstract][Full Text] [Related]
8. Incidence of neuroblastoma after a screening program. Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590 [TBL] [Abstract][Full Text] [Related]
9. Pathology review of screening negative neuroblastomas: a report from the Quebec Neuroblastoma Screening Project. Kawakami T; Monobe Y; Monforte H; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD; Triche TJ; Shimada H Cancer; 1998 Aug; 83(3):575-81. PubMed ID: 9690552 [TBL] [Abstract][Full Text] [Related]
10. Biological aspects of neuroblastomas identified by mass screening in Quebec. Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873 [TBL] [Abstract][Full Text] [Related]
11. Screening for neuroblastoma: a review of the evidence. Chamberlain J J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511 [TBL] [Abstract][Full Text] [Related]
12. A population-based study of neuroblastoma incidence, survival, and mortality in North America. Bernstein ML; Leclerc JM; Bunin G; Brisson L; Robison L; Shuster J; Byrne T; Gregory D; Hill G; Dougherty G J Clin Oncol; 1992 Feb; 10(2):323-9. PubMed ID: 1732433 [TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma mass screening: the arguments for and against. Treuner J; Schilling FH Eur J Cancer; 1995; 31A(4):565-8. PubMed ID: 7576969 [TBL] [Abstract][Full Text] [Related]
14. Poor prognosis neuroblastoma: is screening the answer? Craft AW; Parker L Br J Cancer Suppl; 1992 Aug; 18():S96-101. PubMed ID: 1503935 [TBL] [Abstract][Full Text] [Related]
15. Compliance in a screening program for neuroblastoma. Campion P; Woods WG; Lemieux B Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953 [TBL] [Abstract][Full Text] [Related]
16. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545 [TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma: an enigmatic disease. Brossard J; Bernstein ML; Lemieux B Br Med Bull; 1996 Oct; 52(4):787-801. PubMed ID: 9039732 [TBL] [Abstract][Full Text] [Related]
19. Effects of mass screening on age-specific incidence of neuroblastoma. Bessho F Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611 [TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma of the urinary bladder, preclinically detected by mass screening. Yokoyama S; Hirakawa H; Ueno S; Yabe H; Hiraoka N Pediatrics; 1999 May; 103(5):e67. PubMed ID: 10224211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]